Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...

Investor Webcast Scheduled for 8:00 am ETPRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck ...

PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wednesday. The transcript from the company's ...

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Trial design shift: PDS Biotech added progression-free survival as an interim co-primary endpoint in its Phase III cancer trial to enable a faster FDA review. Cost and size cut: The company reduced ...

Selected by Global Fashion Agenda, PDS, and a slew of brand leaders, these three innovators represent the future of ...

Dr. Matthew Tiscareno will receive the 2026 Carl Sagan Center Director’s Award for scientific leadership, planetary rings ...

The average radio PD is 51. The core listener is 58. John Shomby makes the case for the next generation of programming talent ...

The annual conference in Copenhagen is a microcosm of the industry, offering rare insight into the mood, movements, and ...